Charlottesville, VA, November 3rd, 2016 — Biovista Inc. today announced the signing of a contract with Biotrend Chemikalien GmbH1 for access to Biovista’s2 Vizit3 visual search engine. Biotrend will be offering Vizit as a free resource to visitors of its web site. Vizit is a visual search engine of PubMed articles that allows researchers and … Read More
News
Vizit usage example series: Cancer immunotherapy
The purpose of this post is to demonstrate the utility of Biovista’s Vizit to review and explore specific biomedical domains. In the current example, Vizit is used to identify genes, cell types and microbiome organisms related to Regulatory T cells (Tregs) in the setting of cancer immunotherapy. These entities may have an impact on the … Read More
Biovista patent for the use of tetracyclic pyrazinoindoles issued in the EU
Biovista is pleased to announce that its patent application for the use of tetracyclic pyrazinoindoles has issued in the EU. This new patent (European patent No.: 2375900) has title “METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRZINOINDOLES” was issued on March 2, 2016.
Extreme user profiling: good or bad for search and scientific discovery?
By Andreas Persidis, CEO Biovista Inc. Are you by any chance, like me, beginning to get the feeling that when you are searching online, your digital profile may be getting in the way? That too much of this “personalized” cerebral pampering, too much of this “right information, to the right person at the right time” … Read More
Why Systematic Drug Repurposing is here to stay
Why Systematic Drug Repurposing (SDR) is here to stay. The article gives 5 reasons why SDR will continue to be used as a tool for developing new therapies that are more affordable and make better use of our existing knowledge of disease pathology, drug performance and other date from the real world evidence surrounding treatments.